Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
PD-1 blockade (nivolumab) efficacy remains modest for metastatic sarcoma. In this paper, we present an open-label, non-randomized, non-comparative pilot study of bempegaldesleukin, a CD122-preferential interleukin-2 pathway agonist, with nivolumab in refractory sarcoma at Memorial Sloan Kettering/MD Anderson Cancer Centers (NCT03282344). We report on the primary outcome of objective response rate (ORR) and secondary endpoints of toxicity, clinical benefit, progression-free survival, overall survival, and durations of response/treatment. In 84 patients in 9 histotype cohorts, all patients experienced ≥1 adverse event and treatment-related adverse event; 1 death was possibly treatment-related. ORR was highest in angiosarcoma (3/8) and undifferentiated pleomorphic sarcoma (2/10), meeting predefined endpoints. Results of our exploratory investigation of predictive biomarkers show: CD8 + T cell infiltrates and PD-1 expression correlate with improved ORR; upregulation of immune-related pathways correlate with improved efficacy; Hedgehog pathway expression correlate with resistance. Exploration of this combination in selected sarcomas, and of Hedgehog signaling as a predictive biomarker, warrants further study in larger cohorts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Immune cell content in on-treatment samples differentiates response. A–C Percent (A) PD-1-positive cells (Baseline n = 5 patients [PR], 12 [SD], 31 [PD]; On-Treatment n = 3 [PR], 7 [SD], 23 [PD]), (B) CD8-positive T cells (Baseline n = 4 patients [PR], 11 [SD], 32 [PD]; On-Treatment n = 3 [PR], 7 [SD], 22 [PD]), (C) change in PD-1-positive cells (n = 2 patients [PR], 6 [SD], 20 [PD]), as determined by IHC and categorized by best response and sample time point. A–C Colors indicate trial cohort. ASPS alveolar soft part sarcoma, UPS undifferentiated pleomorphic sarcoma, MFS myxofibrosarcoma. P values are nominal and derived from linear model of positive cells with ORR including sarcoma subtype as a covariate. Boxplot shows the median with hinges at 25th and 75th percentile with whiskers extending to smallest or largest value, no more than 1.5 times interquartile range from the hinges. All values are shown with points. D, F Immune markers in baseline (n = 41 patients) and on-treatment samples (n = 38 patients), respectively, clustered using Manhattan distance and Ward D clustering on the immune populations from RNA-seq (bottom heatmap), with color coding for best response (top row), quartile of percent positive cells for 5 immune markers as detected using IHC, and immune clusters according to the dendrogram. E, G Kaplan–Meier plot of progression-free survival of 3 and 2 immune clusters defined in D and F, respectively. Logrank p values shown for significant comparisons (Baseline n = 8 patients [A], 6 patients [B], n = 27 [C], On-Treatment n = 9 patients [A], On-Treatment n = 29 [C]). Source data are provided as a Source Data file.](https://figures.cochat.ai/paper-figures/bca51a5a7a24446c83377fa888c8f4cb/pilot-study-of-bempegaldesleukin-in-combination-with-nivolumab-in-patients-with-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BS on average show very low TMB: 0.79–1.96 mutations/Mbase in osteosarcoma, 11 , 17 , 18 , 19 ∼0.2 mutations/Mbas in Ewing sarcoma 19 , 20 and <5 mutations/Mbase in chondrosarcoma with some correlation with grade. 21”
From Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial (2025) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TMB is not typically associated with response to ICI efficacy with the exception of rare, TMB-high sarcomas including pleomorphic dermal sarcoma and cutaneous angiosarcoma. 13”
From A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In other sarcoma subtypes, CD8+ T cell infiltration, PD-1 expression and upregulation of immunerelated pathways correlated with improved ORR.”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“However, in osteosarcoma, although it has a higher tumor mutational burden, there is no significant response to the combination therapy [164].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“Tumor mutational burden (TMB), a key indicator of ICI response in most tumors, is generally low across sarcoma subtypes.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Regularization Paths for Generalized Linear Models via Coordinate Descent
Friedman, J., Hastie, T., & Tibshirani, R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v033.i01 · Cited by 19,927
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Near-optimal probabilistic RNA-seq quantification
Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016) · Nature Biotechnology · doi:10.1038/nbt.3519 · Cited by 9,723
The mutational constraint spectrum quantified from variation in 141,456 humans
Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., Alföldi, J., Wang, Q., Collins, R. L., Laricchia, K. M., Ganna, A., Birnbaum, D. P., et al. (2020) · Nature · doi:10.1038/s41586-020-2308-7 · Cited by 9,434
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Research works printed but not linked: 1
- Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv: Genomics (2013).
Cited by
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“However, in osteosarcoma, although it has a higher tumor mutational burden, there is no significant response to the combination therapy [164].”
BackgroundMacrophage Repolarization as a Therapeutic Strategy for Osteosarcoma
Anand, N., Peh, K. H., & Kolesar, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032858 · Cited by 100
“A novel strategy combining nivolumab and an IL-2 agonist, bempegaldesleukin, was evaluated in a pilot study that enrolled 84 patients with relapsed, refractory, advanced, or metastatic sarcoma [60].”
BackgroundInfluentialOsteosarcoma: Current Concepts and Evolutions in Management Principles
Pilavaki, P., Ardakani, A. H. G., Gikas, P. D., & Constantinidou, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082785 · Cited by 81
“Bempegaldesleukin and Nivolumab [24] Pilot study 10 -PR: 0/10 -mPFS: 2 months -mOS: 6.”
BackgroundSubramanian, A., Nemat‐Gorgani, N., Ellis-Caleo, T. J., van IJzendoorn, D. G. P., Sears, T. J., Somani, A., Luca, B. A., Zhou, M. Y., Bradić, M., Torres, I. A., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00743-y · Cited by 72
“RNA was extracted from frozen tissues, library prepped using the TruSeq Stranded mRNA LT kit (Illumina) and sequenced on a HiSeq 4000 (Illumina) as described previously 45 .”
Self-citationCancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy
Chen, M., Bie, L., & Ying, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115514 · Cited by 60
Metadata
- Authors
- D’Angelo, S. P., Richards, A. L., Conley, A. P., Woo, H. J., Dickson, M. A., Gounder, M., Kelly, C., Keohan, M. L., Movva, S., Thornton, K., Rosenbaum, E., Chi, P., Nacev, B., Chan, J. E., Slotkin, E. K., Kiesler, H., Adamson, T., Ling, L., Rao, P., Patel, S., Livingston, J. A., Singer, S., Agaram, N. P., Antonescu, C. R., Koff, A., Erinjeri, J. P., Hwang, S., Qin, L.-X., Donoghue, M. T. A., & Tap, W. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- D’Angelo, Sandra P.
- ORCID
- D’Angelo, Sandra P.
- Richards, Allison L.
- Conley, Anthony P.
- Woo, Hyung Jun
- Dickson, Mark A.
- Gounder, Mrinal
- Kelly, Ciara
- Keohan, Mary Louise
- Movva, Sujana
- Chi, Ping
- Nacev, Benjamin
- Chan, Jason E.
- Slotkin, Emily K.
- Adamson, Travis
- Ling, Lilan
- Patel, Shreyaskumar
- Livingston, Jonathan A.
- Singer, Samuel
- Agaram, Narasimhan P.
- Antonescu, Cristina R.
- Koff, Andrew
- Erinjeri, Joseph P.
- Hwang, Sinchun
- Qin, Li-Xuan
- Donoghue, Mark T. A.
- Tap, William D.
- Venue
- Nature Communications
- Published
- 2022-06-16
- Volume
- 13
- Issue
- 1
- Pages
- 3477-3477
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC9203519
- OpenAlex
- W4283029304
- Cited by
- 60
- References
- 69
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 17 · 2023: 15 · 2022: 3
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Nektar Therapeutics
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- nivolumab, metastatic sarcoma, anti-PD-1 therapy, CD122, combination immunotherapy, objective response rate, angiosarcoma, malignant fibrous histiocytoma, CD8+ T cell infiltration, PD-1 expression, Hedgehog signaling, predictive biomarkers, treatment-related adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Nivolumab, Humans, Interleukin-2, Pilot Projects, Sarcoma, Neoplasms, Second Primary, Hedgehog Proteins, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. https://app.cochat.ai/papers/10.1038/s41467-022-30874-8
- The paper
- D’Angelo, S. P., Richards, A. L., Conley, A. P., Woo, H. J., Dickson, M. A., Gounder, M., Kelly, C., Keohan, M. L., Movva, S., Thornton, K., Rosenbaum, E., Chi, P., Nacev, B., Chan, J. E., Slotkin, E. K., Kiesler, H., Adamson, T., Ling, L., Rao, P., . . . Tap, W. D. (2022). Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. Nature Communications. https://doi.org/10.1038/s41467-022-30874-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.